Sector News

Valeant grabs a Middle Eastern foothold with $800M pact for Egypt’s Amoun

July 20, 2015
Life sciences
Last month, reports said Valeant was stepping up talks on a deal for one of Egypt’s largest drugmakers. And now, it’s pulled the trigger.
 
The serial buyer has agreed to shell out $800 million on Amoun Pharmaceutical–plus contingent payments, it said in a statement. With that, it’ll grab the leading position in Egypt’s domestic pharma market and gain access to brands in the antihypertensive, broad-spectrum antibiotic and antidiarrheal spaces. Amoun is expecting to hit $223.5 million in sales this year and record a top-line swell of about 20%.
 
But Valeant isn’t expecting to keep its new business confined to Egypt. Rather, the Canadian pharma intends for Amoun to “serve as a platform for further expansion” in the Middle East and North Africa, emerging markets that CEO J. Michael Pearson likes for their speedy growth.
 
Beefing up in developing nations has been on Pearson’s agenda for a while now; it was one perk of the proposed Allergan ($AGN) merger, which Actavis eventually spoiled with a white knight swoop-in late last year. Since then, Valeant has made a pair of other acquisitions, though those–a buyout of North Carolina’s Salix and a pickup of bankrupt Dendreon’s assets–focused on different fast-expanding fields (GI and oncology, respectively).
 
Another burgeoning area Valeant’s long had on its radar? Animal health. Last month, sources told The Wall Street Journal it had approached market leader Zoetis, a company in which former deal partner Bill Ackman’s Pershing Square Capital Management holds a stake.
 
By Carly Helfand
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.